$0.159
+0.007 (+4.21%)At close
AIM News
AIM Events
AIM ImmunoTech CEO Addresses FDA Approval of Daraxonrasib
AIM ImmunoTech issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration approval of daraxonrasib and outlining the Company's view of Ampligen's differentiated mechanism. "The FDA's recent approval of daraxonrasib is meaningful progress for people with metastatic pancreatic cancer. In fact, it is significant enough that you may be asking - and I should answer - two questions:Question 1: How is AIM's drug Ampligen different from daraxonrasib? Daraxonrasib is a selective, targeted therapy that inhibits RAS, a major driver of pancreatic cancer. A pivotal, randomized, well-controlled study demonstrated median overall survival of 13.2 months with daraxonrasib compared to 6.7 months with standard chemotherapy, for an improvement of 6.5 months. These results are an important part of the basis for the FDA's approval of daraxonrasib, but they also indicate that many patients on both daraxonrasib and on standard therapy experience disease progression and mortality.... Question 2: What role will Ampligen serve in the future of pancreatic cancer care?... We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have historically limited treatment success in pancreatic cancer"
AIM ImmunoTech Granted New Patent for Cancer Treatment
AIM ImmunoTech announced that the United States Patent and Trademark Office has granted a patent covering the use of the company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer. This newly issued U.S. patent expires December 20, 2039. Ampligen is a wide-spectrum Toll-like receptor 3 agonist, among other biological effects, and has been investigated for the treatment of various cancers, among other conditions. The Company has been issued multiple patents, and has filed multiple additional patent applications, directed to the use of Ampligen for cancer treatment.
AIM ImmunoTech Issues 7.52M Shares at $3.25 Each
AIM ImmunoTech announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7.52M shares of common stock at a purchase price of 3.25c per share. The gross proceeds to the company from the offering are expected to be approximately $2.4M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the company will issue and sell unregistered Series I warrants to purchase up to 15.04M shares of common stock. The offering is expected to close on or about May 21, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. is acting as the exclusive placement agent for the offering.
AIM ImmunoTech Accelerates Pancreatic Cancer Program Progress
AIM ImmunoTech highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, Phase 2 clinical signals, and a strengthening global regulatory and intellectual property position. "The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body of positive late-stage pancreatic ductal adenocarcinoma clinical data, more than 100 subjects treated, Orphan Drug Designations in the U.S. and EU, and a strong global IP portfolio, we believe Ampligen has the potential to be a game-changing therapy in one of the most lethal cancers and a significant driver of long-term stockholder value."
AIM ImmunoTech Announces Preliminary Rights Offering Results of Approximately $1.8M
AIM ImmunoTech announced the preliminary results of its previously announced rights offering which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8M. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions. Each right entitled the holder to purchase one unit, at a subscription price of $1,000 per Unit, consisting of one share of the Company's Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company's Common Stock. The Company anticipates the closing of the Rights Offering will occur on or about March 6, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.
Related articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.